2013
DOI: 10.1001/jamapediatrics.2013.2636
|View full text |Cite
|
Sign up to set email alerts
|

Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants

Abstract: IMPORTANCE Recommendations concerning the appropriate age threshold for respiratory syncytial virus (RSV) prophylaxis in moderate-preterm infants are highly debated. OBJECTIVE To determine the age at which moderate-preterm infants' risk of RSV hospitalization has decreased to the risk observed in low-risk term infants. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of Florida and Texas Medicaid fee-for-service billing records matched to birth certificates from Medicaid beneficiaries aged 0 to 12 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
39
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 48 publications
(42 citation statements)
references
References 47 publications
3
39
0
Order By: Relevance
“…In recent large cohort studies of moderately preterm infants, the majority of whom did not receive palivizumab, 2.5% to 4.9% required hospitalization for RSV infection during the RSV season indicating that more than 95% did not require hospitalization. 40 The rate of hospitalization among infants ≥35 weeks' gestation (5.1/1000) was no different than the rate for term infants (5.3/1000; Table 1). The hospitalization rate of infants ≥30 weeks to 35 weeks' gestation indicate only a slight increase in risk (less than twofold; Tables 1, 2, and 3).…”
Section: Preterm Infants Without Cldmentioning
confidence: 82%
See 2 more Smart Citations
“…In recent large cohort studies of moderately preterm infants, the majority of whom did not receive palivizumab, 2.5% to 4.9% required hospitalization for RSV infection during the RSV season indicating that more than 95% did not require hospitalization. 40 The rate of hospitalization among infants ≥35 weeks' gestation (5.1/1000) was no different than the rate for term infants (5.3/1000; Table 1). The hospitalization rate of infants ≥30 weeks to 35 weeks' gestation indicate only a slight increase in risk (less than twofold; Tables 1, 2, and 3).…”
Section: Preterm Infants Without Cldmentioning
confidence: 82%
“…39 The RSV hospitalization rate increased with decreasing gestational age, with a breakpoint at ≤28 weeks' gestation ( 40 Choosing an appropriate cutoff for gestational age for which palivizumab prophylaxis may be considered for preterm infants without other indications is challenging. Data consistently demonstrate the greatest increase in risk for hospitalization is in preterm infants born before 29 weeks' gestation.…”
Section: Preterm Infants Without Cldmentioning
confidence: 99%
See 1 more Smart Citation
“…In a recent study, ,1% of the Medicaid birth cohorts in Florida and Texas received palivizumab. 27 In another multicenter study, only 9% of hospitalized children had ever received palivizumab. 2 Finally, infants who receive palivizumab are generally those with prematurity or CCC, conditions that may also predispose them to death.…”
Section: Discussionmentioning
confidence: 99%
“…Surprisingly, Ambrose suggests greater use of palivizumab prophylaxis is justified by quoting Winterstein et al 4 This publication evaluated the age at which moderate preterm Medicaid-enrolled infants without other indications for RSV prophylaxis showed an RSV hospitalization risk similar to that of healthy term infants in Florida and Texas. Although moderately premature infants show about twice the risk of RSV hospitalization during the first month of life, this risk drops to no recognizable differences at an age of 4 months.…”
Section: Authors' Responses In Response To the Letter From Ambrosementioning
confidence: 99%